

DRUG NAME: Regorafenib**SYNONYM(S)**¹: BAY 73-4506, regorafenib monohydrate²**COMMON TRADE NAME(S)**: STIVARGA®**CLASSIFICATION**: molecular targeted therapy*Special pediatric considerations are noted when applicable, otherwise adult provisions apply.***MECHANISM OF ACTION:**

Regorafenib is a multiple receptor tyrosine kinase (RTK) inhibitor. RTKs are involved in cell proliferation, cell survival and tumour progression, depending on the specific kinase.³ Regorafenib and/or its active metabolites (M-2, M-5) inhibit kinases involved in tumour angiogenesis (VEGFR-1, VEGFR-2, VEGFR-3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF, BRAFV600E), and maintenance of tumour microenvironment (PDGFR, FGFR).^{1,2}

PHARMACOKINETICS:

Oral Absorption	bioavailability 70-83%; C _{max} 3-4 h; fat content in meals results in variable exposure, optimal plasma levels achieved after a low-fat, low-calorie meal (<30% fat, ~300-550 calories)	
Distribution	multiple peak concentrations at 4, 8, and 24 h post-daily dosing due to enterohepatic circulation of drug and metabolites	
	cross blood brain barrier?	no information found
	volume of distribution	88 L
	plasma protein binding	99.5% (regorafenib), 99.8% (M-2), 99.95% (M-5)
Metabolism	primarily in the liver by oxidation (CYP 3A4) and glucuronidation (UGT 1A9)	
	active metabolite(s)	M-2 (N-oxide), M-5 (N-oxide and N-desmethyl)
	inactive metabolite(s)	none specified
Excretion	metabolites may be reduced or hydrolyzed in the GI tract by microbial flora and allow for reabsorption of unconjugated drug and metabolites (enterohepatic circulation)	
	urine	19%
	feces	71% (47% as parent compound, 24% as metabolites)
	terminal half life	20-30 h (regorafenib and M-2), 40-100 h (M-5)
	clearance	no information found

Adapted from standard reference² unless specified otherwise.**USES:****Primary uses:**

- *Colorectal cancer
- *Gastrointestinal stromal tumour (GIST)
- *Liver cancer

*Health Canada approved indication

Other uses:**SPECIAL PRECAUTIONS:****Contraindications:**

- history of hypersensitivity reaction to regorafenib or sorafenib²
- children and adolescents less than 18 years²
- pregnant women and women at risk of becoming pregnant²

Caution:

- **impaired wound healing** has been associated with vascular endothelial growth factor (VEGF) inhibitors; stop regorafenib at least 2 weeks prior to surgery and re-initiate post-surgery based on clinical assessment of the wound site²
- **cardiac adverse events**, including arrhythmias, congestive heart failure and myocardial ischemia, have been reported with regorafenib; use with caution in patients at risk for or who have a history of cardiac events, including those who are bradycardic, have a history of arrhythmia, or are taking heart rate lowering drugs²
- **hypertension** has been observed with regorafenib; hypertension should be well controlled prior to starting treatment²

Special populations:

- **Asian** patients have reported a higher incidence of hand-foot skin reaction²
- patients with **hepatic impairment** may have a higher incidence of adverse events compared to patients with normal baseline hepatic function²
- **female** patients have reported a higher overall incidence of serious adverse events compared to male patients²
- patients who are **65 years or older** have reported a higher incidence of severe hypertensive events²

Carcinogenicity: no information found

Mutagenicity: Not mutagenic in Ames test and in mammalian *in vitro* and *in vivo* mutation tests. M-2 metabolite is clastogenic in a mammalian *in vitro* chromosome test.²

Fertility: Atrophy/degeneration of seminiferous tubules, oligospermia, aspermia, as well as decreased corpora lutea and developing follicles have been reported in animal studies.²

Pregnancy: FDA Pregnancy Category D.³ There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).

In animal studies, regorafenib has been associated with developmental toxicity, teratogenicity, and pregnancy loss. Animal toxicology studies have reported hypertrophy of epiphyseal growth plates and abnormalities in growing incisors, indicating a potential risk for children and adolescents. Patients and partners of male patients should use contraception throughout therapy and for 8 weeks after discontinuation of therapy.²

Breastfeeding is not recommended due to the potential secretion into human breast milk. In animal studies, regorafenib and metabolites have been excreted in milk.^{2,3}

SIDE EFFECTS:

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important.^{4,5} When placebo-controlled trials are available, adverse events will generally be included if the incidence is $\geq 5\%$ higher in the treatment group.^{6,7}

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in bold, italics	
blood and lymphatic system/ febrile neutropenia	anemia (5%, severe 1-2%) ⁶
	thrombocytopenia (6-15%, severe 1-3%)

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in bold, italics	
cardiac	cardiac adverse events (3-9%, severe 1%); see paragraph following Side Effects table
endocrine	hypothyroidism (13%)
gastrointestinal	<i>emetogenic potential: low</i> ⁸
	constipation (15%, severe 1%) ⁷
	diarrhea (34-47%, severe 1-8%) ^{2,6}
	gastrointestinal perforation or fistula (2%); permanently discontinue treatment
	nausea (20%, severe 2%)
	stomatitis/mucosal inflammation (16-38%, severe 1-3%) ^{2,6,7}
	vomiting (17%, severe <1%)
general disorders and administration site conditions	asthenia/fatigue (39-64%, severe 1-15%) ^{2,7}
	fever (10-28%, severe 1-2%) ^{2,6}
	myalgia (14%, severe 1%) ⁷
	pain (29%, severe 1-2%)
hepatobiliary	hepatobiliary disorders (20%, severe 2%); see paragraph following Side Effects table
infections and infestations	infection (31-32%, severe 1-7%)
investigations	hyperbilirubinemia (9-19%, severe 1-6%) ^{2,6}
	increased lipase (6%)
	increased transaminases (11%, severe 3%)
	weight loss (14-32%, severe <1%)
metabolism and nutrition	decreased appetite (21-47%, severe 1-5%) ^{2,7}
	hypocalcemia (6%)
	hypokalemia (8%)
	hypophosphatemia (5-6%)
musculoskeletal and connective tissue	musculoskeletal stiffness (14%)
nervous system	dysgeusia (7-10%) ^{2,6}
	dysphonia (11-39%, severe <1%) ^{2,6,7}
	headache (16%)
	reversible posterior leukoencephalopathy syndrome ; see paragraph following Side Effects table
renal and urinary	proteinuria (7-8%, severe 1%) ^{2,6}
skin and subcutaneous tissue	alopecia (7-24%, severe 2%) ^{2,6}
	dry skin (5-9%) ^{2,6}
	erythema multiforme, Stevens-Johnson Syndrome (<1%)
	hand-foot skin reaction (47-67%, severe 17-22%); see paragraph following Side Effects table

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in bold, italics	
	rash (18-30%, severe 2-7%)
vascular	hemorrhage (5-21%, severe 1-2%) ^{2,6} ; see paragraph following Side Effects table
	hypertension (28-59%, severe 1-2%) ^{2,6} ; see paragraph following Side Effects table

Adapted from standard reference² unless specified otherwise.

Cardiac adverse events, including myocardial ischemia and/or infarction, have been associated with regorafenib. Use with caution in patients with a history of ischemic heart disease. For new or acute onset cardiac ischemia and/or infarction, hold regorafenib until resolution; reinstate therapy only after consideration of potential benefits and risks. Permanently discontinue therapy if there is no resolution of symptoms.²

Hypertension usually occurs in the first cycle of treatment. Monitor blood pressure weekly for the first 6 weeks of treatment and regularly thereafter as indicated. Hypertension may be treated with a combination of standard anti-hypertensive therapy and regorafenib dose reduction or interruption. Discontinue regorafenib for hypertensive crisis or severe/persistent hypertension despite anti-hypertensive therapy.²

Hand-foot skin reaction (HFSR) has been reported with an incidence of 47-67%. Management of HFSR may include symptomatic and supportive measures,³ dose reduction, or interruption of regorafenib. In severe or persistent cases despite dose reductions, permanently discontinue regorafenib.^{1,2}

Hemorrhagic events involving the respiratory, genitourinary, and gastrointestinal tracts have been reported with regorafenib and are sometimes fatal. Patients on warfarin should be closely monitored. Discontinue regorafenib in patients with severe or life threatening hemorrhage.²

Abnormal **liver function tests** and **hepatic dysfunction** with fatal outcomes have been reported with regorafenib. Dose reduction or interruption of regorafenib may be required. Permanently discontinue regorafenib if patient develops²:

- AST or ALT greater than 20 times the upper limit of normal (grade 4),
- AST or ALT greater than 3 times the upper limit of normal with concurrent bilirubin greater than 2 times the upper limit of normal, or
- re-occurrence of AST or ALT greater than 5 times the upper limit of normal (grade3) despite dose reduction.

Reversible posterior leukoencephalopathy syndrome (RPLS), a rare neurologic disorder, has been reported with regorafenib. Symptoms may include seizures, headache, altered mental status, visual disturbance, or cortical blindness, with or without associated hypertension. Brain imaging is necessary to confirm diagnosis. Discontinue regorafenib when signs/symptoms of RPLS are present and provide supportive management. The safety of reinitiating treatment with regorafenib is not known.²

For any **grade 3 or 4** adverse reactions (not related to HFSR, hypertension, or abnormal liver function tests), interrupt regorafenib therapy and resume at a reduced dose once recovered to Grade 2.² For recurrence of **grade 4** adverse reactions, reinstate therapy only after consideration of potential benefits and risks to the patient. If patient is unable to tolerate 80 mg dose, permanently discontinue regorafenib.²

INTERACTIONS:

AGENT	EFFECT	MECHANISM	MANAGEMENT
5-fluorouracil ³	regorafenib does not affect 5-fluorouracil pharmacokinetics		

AGENT	EFFECT	MECHANISM	MANAGEMENT
irinotecan ²	irinotecan exposure increased by 28%; SN-38 metabolite AUC increased by 44%	regorafenib inhibition of glucuronidation via UGT1A1 and UGT1A9	clinical significance is unknown; monitor for increased irinotecan adverse effects
ketoconazole ²	regorafenib AUC increased by 33%; exposure of metabolites decreased by 94% (M-2) and 93% (M-5)	ketoconazole inhibition of CYP 3A4	avoid concurrent use with strong CYP 3A4 inhibitors
midazolam ²	midazolam AUC increased by 12% and C _{max} increased by 28%	regorafenib inhibition of CYP 3A4	not considered clinically significant; action not required
omeprazole ²	regorafenib does not affect omeprazole exposure		
oxaliplatin ³	oxaliplatin AUC increased by 39%	regorafenib inhibition of glucuronidation via UGT1A1 and UGT1A9	clinical significance is unknown; monitor for increased oxaliplatin adverse effects
rifampin ²	regorafenib AUC decreased by 50%; M-5 metabolite exposure increased by 3-4 times. No change in M-2 metabolite.	rifampin induction of CYP 3A4	avoid concurrent use with strong CYP 3A4 inducers
rosiglitazone ²	regorafenib does not affect rosiglitazone exposure		
warfarin ^{1,2}	S-warfarin AUC increased by 25% and C _{max} increased by 26%	regorafenib inhibition of CYP 2C9	monitor INR regularly; watch for increased bleeding

Grapefruit and grapefruit juice may inhibit CYP 3A4 metabolism of regorafenib in the intestinal wall and theoretically increase regorafenib plasma levels and reduce exposure for its metabolites; clinical significance is unknown.¹

Regorafenib undergoes enterohepatic circulation. Concurrent use with antibiotics which disrupt the gastrointestinal tract flora and affect enterohepatic circulation of regorafenib may alter regorafenib exposure; clinical significance is unknown.²

SUPPLY AND STORAGE:

Oral: Bayer Inc. supplies regorafenib as 40 mg film-coated tablets. Store in original container at room temperature. Keep bottle tightly closed after opening and do not remove the desiccant.²

Additional information: Once bottle is opened, discard remainder after 7 weeks.⁹⁻¹¹

DOSAGE GUIDELINES:

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response, and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count (ANC). Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due to cytotoxic/radiation therapy or with other toxicities.

Adults:

BC Cancer usual dose noted in **bold, italics**

<i>Oral</i> ^{2,12,13} :	<p>Cycle Length: 4 weeks: 160 mg (range 80 -160 mg) PO once daily for 21 consecutive days starting on day 1 (total dose per cycle 3360 mg [range 1680-3360 mg])</p> <p>Round dose to the nearest 40 mg. Administer at the same time each day after a light, low-fat, low-calorie meal (<30% fat, ~300-550 calories).</p>
<i>Concurrent radiation:</i>	no information found
<i>Dosage in myelosuppression:</i>	modify according to protocol by which patient is being treated; if no guidelines available, refer to Appendix "Dosage Modification for Myelosuppression"
<i>Dosage in renal failure:</i>	no adjustment required for mild to severe impairment ¹⁴ ; no information found for end-stage renal disease
<i>Dosage in hepatic failure:</i>	no adjustment recommended for mild to moderate hepatic impairment ² ; however, the incidence of adverse reactions is reported to increase with hepatic impairment ¹⁴ no information found for severe hepatic impairment;
<i>Dosage in dialysis:</i>	no information found
<u>Children:</u>	not recommended for use in children and adolescents ²

REFERENCES:

1. Lexi-Drugs® (database on the Internet). Regorafenib. Lexi-Comp Inc., 24 April 2014. Available at: <http://online.lexi.com>. Accessed 30 April 2014.
2. Bayer Inc. STIVARGA® product monograph. Toronto, Ontario; 2 October 2013.
3. AHFS Drug Information® (database on the Internet). Regorafenib. Lexi-Comp Inc., 27 March 2014. Available at: <http://online.lexi.com>. Accessed 30 April 2014.
4. John Paul McGhie MD. Personal communication. BC Cancer Agency Gastrointestinal Tumour Group; 14 July 2014.
5. Meg Knowling MD. Personal communication. BC Cancer Agency Sarcoma Tumour Group; 16 July 2014.
6. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013;381:303-312.
7. Demetri GD, Reichardt P, Kang Y, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013;381:295-302.
8. BC Cancer Agency. (SCNAUSEA) Guidelines for Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting in Adults. Vancouver, British Columbia: BC Cancer Agency; 1 Mar 2012.
9. Don Renaud. Personal communication. Medical Information Associate, Bayer Inc.; 26 June 2015.
10. Bayer HealthCare Pharmaceuticals Inc. STIVARGA® full prescribing information. Wayne, New Jersey, USA; April 2015.
11. European Medicines Agency. STIVARGA® summary of product characteristics. London, United Kingdom: European Medicines Agency; 23 June 2015.
12. BC Cancer Agency Sarcoma Tumour Group. (USAAVGR) BCCA Protocol Summary for Third Line Therapy of Advanced Gastrointestinal Stromal Cell Tumours (GIST's) Using Regorafenib. Vancouver, British Columbia: BC Cancer Agency; 1 Feb 2015.
13. BC Cancer Gastrointestinal Tumour Group. (UGIREGO) BC Cancer Protocol Summary for Treatment of Advanced Hepatocellular Carcinoma Using Regorafenib (STIVARGA®). Vancouver, British Columbia: BC Cancer; 1 July 2019.
14. Bayer Inc. STIVARGA® product monograph. Mississauga, Ontario; 30 January 2019.